News & events

Press releases

25 February 2021, Sophia Antipolis, France

Median strengthens its iBiopsy® leadership team with the appointment of Thomas Bonnefont as Chief Operating and Commercial Officer and the appointment of Mike Doherty as Sr. Strategy Advisor, Product Development

These two appointments follow a series of first successful achievements for iBiopsy® in 2020 and early 2021. Median prepares to launch its iBiopsy® product development plan, including regulatory aspects, define its go-to-market strategy then expand its iBiopsy® operations globally.

Read more
See all press releases

Conferences

November 29 - December 4, 2020 | Virtual Event

RSNA 2020

Median will be exhibiting at the RSNA 2020 Annual Meeting, which will take place from November 29 to December 4. Stop by our virtual booth to learn more about our  Imaging Phenomics platform iBiopsy®. Happy to see you there during the whole exhibition duration, from November 30 to December 3.

Visit conference website
See all conferences

In the press

iBiopsy® for Precision Medicine

Check out our paper published in the European Medical Journal on December 13, 2018 in order to educate the oncology specialists across Europe and the US as to the high-throughput artificial intelligence powered image-base phenotyping platform, iBiopsy® -> http://viewer.zmags.com/publication/647c38a3#/647c38a3/50

Abstract

A high-throughput artificial intelligence-powered image-based phenotyping platform, iBiopsy® (Median Technologies, Valbonne, France), which aims to improve precision medicine, is discussed in the presented review. The article introduces novel concepts, including high-throughput, fully automated imaging biomarker extraction; unsupervised predictive learning; large-scale content-based image-based similarity search; the use of large-scale clinical data registries; and cloud-based big data analytics to the problems of disease subtyping and treatment planning. Unlike electronic health record-based approaches, which lack the detailed radiological, pathological, genomic, and molecular data necessary for accurate prediction, iBiopsy® generates unique signatures as fingerprints of disease and tumor subtypes from target images. These signatures are then merged with any additional omics data and matched against a large-scale reference registry of deeply phenotyped patients. Initial applications targeted include hepatocellular carcinoma and other chronic liver diseases, such as nonalcoholic steatohepatitis. This new disruptive technology is expected to lead to the identification of appropriate therapies targeting specific molecular pathways involved in the detected phenotypes to bring personalised treatment to patients, taking into account individual biological variability, which is the principal aim of precision medicine.

See all in the press

Blog

See all blog entries

Webinars

FEBRUARY 18, 2021

Imaging services in clinical trials: using Business Intelligence-based reporting tools to optimize operations efficiency

Efficient reporting tools are a must have when managing the vast amount of data in clinical trials. However, reports are only meaningful when they are based on accurate operational data and challenges can arise when data is constantly changing and is integrated from multiple sources using various formats.

This 45-minute presentation provides an overview on how Business Intelligence (BI) is used at Median to develop comprehensive and meaningful reporting tools based on high quality data, for better operational efficiency. Here are some insights we will be discussing:

  • BI for data management in clinical trials, including 2 main components: data integration and data visualization,
  • BI-based data integration is the most efficient way to manage clinical data coming from multiple sources using different formats,
  • BI-based data visualization enables the aggregation of data in powerful reports, providing insights on quality monitoring, activity, forecasts, and risk management for clinical trials,
  • Implementing a BI based reporting tool is an exceedingly profitable investment for both clients and imaging CROs! Let us explain why!

Presenters

Watch webinar video
See all webinars